Squarepoint Ops LLC Sells 76,385 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Squarepoint Ops LLC cut its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 66.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,521 shares of the company's stock after selling 76,385 shares during the period. Squarepoint Ops LLC's holdings in MiMedx Group were worth $371,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of MDXG. IMG Wealth Management Inc. bought a new stake in MiMedx Group during the 4th quarter valued at approximately $28,000. Van ECK Associates Corp purchased a new stake in MiMedx Group during the 4th quarter valued at approximately $40,000. Tower Research Capital LLC TRC raised its position in shares of MiMedx Group by 77.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after buying an additional 2,837 shares during the last quarter. AlphaQuest LLC bought a new stake in shares of MiMedx Group during the fourth quarter valued at approximately $88,000. Finally, Savant Capital LLC purchased a new position in shares of MiMedx Group in the fourth quarter worth $100,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Price Performance

NASDAQ MDXG traded down $0.04 during trading on Monday, hitting $6.45. 484,055 shares of the stock traded hands, compared to its average volume of 687,754. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The firm has a 50-day simple moving average of $6.83 and a 200-day simple moving average of $8.03. The company has a market capitalization of $952.68 million, a P/E ratio of 11.73 and a beta of 1.82.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, meeting analysts' consensus estimates of $0.06. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $88.21 million during the quarter, compared to the consensus estimate of $86.32 million. As a group, analysts predict that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Insider Buying and Selling at MiMedx Group

In related news, CEO Joseph H. Capper purchased 200,000 shares of the firm's stock in a transaction that occurred on Friday, May 2nd. The shares were bought at an average price of $6.34 per share, for a total transaction of $1,268,000.00. Following the acquisition, the chief executive officer now owns 529,530 shares of the company's stock, valued at approximately $3,357,220.20. This represents a 60.69% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the sale, the insider now owns 310,836 shares of the company's stock, valued at approximately $2,452,496.04. This represents a 1.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 60,461 shares of company stock worth $477,301 over the last 90 days. 1.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th. Wall Street Zen upgraded shares of MiMedx Group from a "hold" rating to a "buy" rating in a research note on Friday.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.